Widespread shortages of EpiPen, an epinephrine autoinjector for the treatment of anaphylaxis, have been resolved.

The Therapeutic Goods Administration (TGA) confirmed this week the supply had returned to normal following a worldwide shortage that lasted almost a year.

Issues with overseas manufacturers of the Mylan product in April 2018 had international ramifications, forcing those with serious allergies to insect stings/bites, foods, drugs and other substances to seek alternative treatments.

“Consumers and health professionals are advised that the shortage of EpiPen 300 mcg adrenaline auto-injectors has been resolved,” the regulator announced on Wednesday.

“The sponsor, Alphapharm Pty Ltd (trading as Mylan Australia), has confirmed that there is sufficient supply of EpiPen 300 mcg adrenaline auto-injectors to meet current patient needs in Australia.”

The TGA updated the public five months ago, stating supply had started increasing, but was still limited.

For more information about the replenishment of EpiPen levels, head to the TGA website.